TRCT
ZNTL icon

Tower Research Capital (TRC)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1K Buy
3,115
+1,981
+175% +$7.91K ﹤0.01% 3778
2026
Q1 		$2.65K Buy
+1,134
New +$2.93K ﹤0.01% 4441
2025
Q4 		– Sell
-29,386
Closed -$44.4K – 5680
2025
Q3 		$44.4K Buy
29,386
+12,272
+72% +$18.4K ﹤0.01% 2622
2025
Q2 		$19.9K Buy
17,114
+11,873
+227% +$15.7K ﹤0.01% 3686
2025
Q1 		$8.33K Sell
5,241
-3,394
-39% -$7.32K ﹤0.01% 3901
2024
Q4 		$26.2K Buy
8,635
+686
+9% +$2.25K ﹤0.01% 2980
2024
Q3 		$29.3K Sell
7,949
-29,536
-79% -$107K ﹤0.01% 3017
2024
Q2 		$153K Buy
37,485
+37,421
+58,470% +$418K ﹤0.01% 2269
2024
Q1 		$1.01K Sell
64
-3,551
-98% -$48.8K ﹤0.01% 5347
2023
Q4 		$54.8K Buy
3,615
+2,589
+252% +$37.8K ﹤0.01% 3069
2023
Q3 		$20.6K Sell
1,026
-5,894
-85% -$150K ﹤0.01% 3345
2023
Q2 		$195K Buy
6,920
+4,829
+231% +$116K 0.01% 1573
2023
Q1 		$36K Sell
2,091
-487
-19% -$9.86K ﹤0.01% 2821
2022
Q4 		$51K Sell
2,578
-3,443
-57% -$74K ﹤0.01% 2341
2022
Q3 		$130K Sell
6,021
-1,619
-21% -$44.3K ﹤0.01% 2326
2022
Q2 		$215K Buy
7,640
+7,122
+1,375% +$189K ﹤0.01% 1719
2022
Q1 		$24K Sell
518
-3,424
-87% -$185K ﹤0.01% 3381
2021
Q4 		$331K Buy
3,942
+1,325
+51% +$103K 0.01% 1409
2021
Q3 		$175K Sell
2,617
-467
-15% -$26.9K ﹤0.01% 1941
2021
Q2 		$164K Buy
3,084
+1,640
+114% +$87.8K ﹤0.01% 2072
2021
Q1 		$63K Buy
1,444
+726
+101% +$31.3K ﹤0.01% 2935
2020
Q4 		$37K Sell
718
-8,516
-92% -$384K ﹤0.01% 3404
2020
Q3 		$302K Buy
9,234
+8,724
+1,711% +$305K ﹤0.01% 2184
2020
Q2 		$24K Buy
+510
New +$19.6K ﹤0.01% 3594

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Tower Research Capital (TRC)'s ZNTL Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Zentalis Pharmaceuticals (ZNTL) stake by 175% in Q2 2026, buying an estimated $7.91K and bringing the position to 3,115 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3778.

Tower Research Capital (TRC) first reported a position in ZNTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $331K in Q4 2021. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Tower Research Capital (TRC) held 3,115 shares of Zentalis Pharmaceuticals worth $15.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,981 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $7.91K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3778 holding.
  • Tower Research Capital (TRC) first reported a position in Zentalis Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Zentalis Pharmaceuticals position peaked at $331K in Q4 2021.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.